Nice says more evidence needed on effectiveness of tirzepatide, sold under brand name Mounjaro
A weight-loss jab has been rejected for NHS use by England’s drugs watchdog.
The National Institute for Health and Care Excellence (Nice), which provides recommendations and guidance to health practitioners, said more evidence was needed on the clinical and cost-effectiveness of tirzepatide, which is sold under the brand name Mounjaro, before it could be recommended for NHS use.
